Bamlanivimab

Summary

Bamlanivimab (CHEMBL4650379) is a phase-3 clinical-stage antibody; indicated across 1 condition including severe acute respiratory syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 1 condition
• Clinical trials: 16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650379
Name	Bamlanivimab
Type	Antibody
Max phase	3

Also known as: Bamlanivimab, LY-3819253, LY-CoV555, Ly3819253, LY3819253, BAMLANIVIMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	CoV Spike glycoprotein	Binding

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE3	4
PHASE4	3
PHASE2	3
PHASE2/PHASE3	2
PHASE1	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04656691	PHASE4	TERMINATED	At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19
NCT04790786	PHASE4	TERMINATED	UPMC OPTIMISE-C19 Trial, a COVID-19 Study
NCT04796402	PHASE4	UNKNOWN	A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19
NCT04427501	PHASE2/PHASE3	COMPLETED	A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
NCT04497987	PHASE3	COMPLETED	A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
NCT04501978	PHASE3	COMPLETED	ACTIV-3: Therapeutics for Inpatients With COVID-19
NCT04518410	PHASE2/PHASE3	COMPLETED	ACTIV-2: A Study for Outpatients With COVID-19
NCT05205759	PHASE3	TERMINATED	Non-inferiority Trial on Monoclonal Antibodies in COVID-19
NCT05780268	PHASE3	COMPLETED	LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT04634409	PHASE2	COMPLETED	A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
NCT04701658	PHASE2	COMPLETED	A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
NCT04840459	PHASE2	UNKNOWN	Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting
NCT04411628	PHASE1	COMPLETED	A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
NCT04537910	PHASE1	COMPLETED	A Study of LY3819253 (LY-CoV555) in Healthy Participants
NCT04603651	Not specified	NO_LONGER_AVAILABLE	Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19
NCT05268601	Not specified	COMPLETED	COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).